Coronary Artery Bypass Grafts Products Market Size, Share, Growth, and Industry Analysis, By Types (Saphenous Vein Grafts, Internal Thoracic Artery Grafts, Other) , Applications (Traditional CABG, Nontraditional CABG) and Regional Insights and Forecast to 2033

Coronary Artery Bypass Grafts (CABG) Products Market Size

The global Coronary Artery Bypass Grafts (CABG) Products Market was valued at USD 135.26 million in 2024 and is projected to reach USD 138.78 million in 2025, growing to USD 170.42 million by 2033. With a CAGR of 2.6% during the forecast period (2025-2033), the market is driven by the rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive procedures, and advancements in vascular graft technology.

The US CABG Products Market is expanding due to growing healthcare expenditures, increasing incidence of heart disease, and strong demand for innovative grafting solutions. Government support for cardiovascular research and rising awareness of preventive cardiac care are further accelerating market growth.

The coronary artery bypass grafts (CABG) products market is witnessing significant growth due to the rising prevalence of cardiovascular diseases globally. With over 30% of global deaths attributed to heart diseases, the demand for CABG procedures is increasing. Advancements in biocompatible graft materials and minimally invasive surgical techniques are further fueling market expansion.

Additionally, an aging population, with over 20% of individuals above 60 years suffering from coronary artery disease, is driving the need for effective surgical interventions. The market is also witnessing a shift towards synthetic and tissue-engineered grafts, enhancing procedural efficiency and patient outcomes.

Coronary Artery Bypass Grafts Products Market Trends 

The CABG products market is experiencing a surge due to increased adoption of off-pump coronary artery bypass (OPCAB) procedures, which has grown by over 40% in the past decade. The rise in biological grafts usage, particularly in developed nations, has led to a 35% increase in demand for arterial grafts over traditional vein grafts. Technological advancements in drug-eluting grafts, which reduce restenosis risk by over 50%, are further boosting adoption.

With robotic-assisted surgeries rising by 60%, hospitals are integrating AI and 3D printing technologies for graft customization, leading to a 45% improvement in procedural precision. Additionally, the prevalence of diabetes, affecting over 35% of CABG patients, has intensified the need for more durable and biocompatible graft materials.

North America and Europe collectively account for over 70% of the market, driven by high healthcare expenditure and advanced surgical infrastructure. Meanwhile, Asia-Pacific is witnessing a 50% growth in procedural volume due to increasing healthcare accessibility and a rising elderly population. The demand for biopolymer-based grafts has grown by 30%, as they offer enhanced longevity and reduced rejection rates.

Coronary Artery Bypass Grafts Products Market Dynamics

DRIVER

"Growing Incidence of Cardiovascular Diseases"

Cardiovascular diseases account for over 30% of global deaths, driving the demand for CABG procedures. The increasing prevalence of obesity and hypertension, affecting more than 40% of adults globally, has accelerated the need for surgical interventions. Additionally, over 50% of cardiac surgeries now incorporate arterial grafts, improving patient outcomes. Growing investments in biodegradable and tissue-engineered grafts, which have seen a 60% rise in adoption, are further fueling market expansion. The demand for minimally invasive procedures has surged by 55%, reducing hospital stays and improving post-operative recovery rates.

RESTRAINT

"High Procedural Costs and Limited Reimbursement"

The cost of CABG surgeries remains a major barrier, with expenses rising by over 40% in the past decade due to technological advancements and specialized equipment requirements. Limited reimbursement policies in developing regions hinder market growth, affecting over 50% of uninsured patients. Additionally, post-surgical complications, impacting nearly 35% of patients, increase long-term healthcare expenditures. The availability of alternative treatments like angioplasty and stenting, which have seen a 45% rise in preference, is also limiting the adoption of CABG procedures. The high cost of biocompatible grafts, which has surged by 30%, further restricts widespread usage.

OPPORTUNITY

" Advancements in Tissue-Engineered Grafts"

The market is witnessing a 50% increase in the development of tissue-engineered grafts that improve biocompatibility and reduce graft failure rates. The adoption of stem cell-based therapies has grown by 40%, offering potential for personalized treatments. Additionally, hybrid grafts, which combine synthetic and biological materials, have shown a 60% success rate improvement in complex cases. Emerging economies are investing in cardiac care infrastructure, with a 35% rise in funding for advanced surgical procedures. The integration of 3D printing in graft development, expected to grow by 70%, is opening new avenues for personalized medicine.

CHALLENGE

" Post-Surgical Complications and Graft Failures"

Graft failure rates remain a significant challenge, with over 30% of vein grafts experiencing occlusion within a year. The incidence of post-surgical infections has risen by 25%, increasing the risk of complications. Additionally, nearly 40% of patients require revision surgeries within five years, affecting long-term treatment efficacy. The shortage of specialized cardiac surgeons, with a 20% decline in new professionals entering the field, is further impacting surgical accessibility. The regulatory approval process for novel graft materials remains stringent, delaying market entry by over 45% for new products, slowing innovation and adoption rates.

Segmentation Analysis

The coronary artery bypass grafts (CABG) products market is segmented based on type and application. By type, the market includes saphenous vein grafts, internal thoracic artery grafts, and others, each playing a crucial role in CABG procedures. Internal thoracic artery grafts are preferred in over 60% of cases due to their durability and long-term patency rates. By application, the market is divided into traditional CABG and nontraditional CABG, with traditional procedures accounting for nearly 70% of surgeries. However, the rising adoption of nontraditional CABG techniques, such as minimally invasive and robotic-assisted procedures, has surged by 50% in recent years.

By Type

• Saphenous Vein Grafts: Saphenous vein grafts (SVGs) are used in over 40% of CABG procedures, making them a widely utilized option. However, their patency rate drops by 50% within ten years due to occlusion risks. SVGs are commonly harvested from the leg veins and are preferred for multiple bypass procedures due to their availability. The use of endoscopic vein harvesting (EVH) has increased by 45%, reducing post-operative complications. Despite their usage, the failure rate in diabetic patients is 30% higher, leading to a growing preference for arterial grafts. However, ongoing research in drug-eluting vein grafts aims to improve long-term outcomes.
• Internal Thoracic Artery Grafts: Internal thoracic artery (ITA) grafts have the highest patency rate, remaining functional in over 85% of cases after ten years. This graft type is now utilized in 60% of CABG surgeries, particularly for the left anterior descending (LAD) artery. ITA grafts significantly reduce the risk of revascularization by 40% compared to vein grafts. With robotic-assisted surgery increasing by 50%, the precision of ITA harvesting has improved. However, limited availability and 20% longer surgical duration hinder widespread adoption. The market is also seeing a 35% increase in research on synthetic artery grafts mimicking ITA functionality.
• Other Grafts: Alternative grafts, including radial artery grafts and gastroepiploic artery grafts, are gaining traction, with a 30% increase in usage over the past decade. Radial artery grafts have a patency rate of over 75% at ten years, making them a viable alternative for younger patients. However, 40% of patients experience vasospasm, limiting their widespread adoption. Gastroepiploic artery grafts are used in complex cases but are selected in only 10% of procedures due to surgical complexity. Hybrid grafting techniques, which combine arterial and synthetic grafts, have demonstrated a 50% improvement in multi-vessel bypass surgeries.

By Application

• Traditional CABG: Traditional CABG remains the gold standard, accounting for over 70% of procedures worldwide. The open-heart surgery approach allows for multiple bypasses in a single operation, improving long-term survival rates by 55% compared to angioplasty. However, longer hospital stays and post-surgical complications affect 35% of patients, increasing recovery time. The use of heart-lung machines, which has seen a 30% decline, is being replaced by off-pump techniques. Despite the challenges, traditional CABG remains preferred for high-risk patients, with 80% of cardiac surgeons still recommending it as the most effective treatment for complex multi-vessel disease.
• Nontraditional CABG: Nontraditional CABG procedures, including off-pump CABG (OPCAB) and robotic-assisted CABG, are rapidly growing, with a 50% increase in adoption. OPCAB reduces the risk of post-operative complications by 45%, leading to faster recovery times. Robotic-assisted CABG procedures have expanded by 60%, enhancing precision and minimizing surgical trauma. Hybrid revascularization techniques, which combine CABG and stenting, have witnessed a 40% increase, providing better flexibility in treating complex coronary artery disease. With technological advancements improving surgical efficiency, over 35% of hospitals are integrating minimally invasive techniques, reducing hospital stays by 30% compared to traditional CABG.



Request a Free sample    to learn more about this report.

Coronary Artery Bypass Grafts Products Regional Outlook 

The CABG products market varies significantly across regions based on healthcare infrastructure, disease prevalence, and technological adoption. North America leads the market, contributing over 40% of global procedures due to high cardiovascular disease incidence and advanced surgical techniques. Europe follows, with over 35% of hospitals integrating robotic-assisted CABG. The Asia-Pacific region is witnessing a 50% increase in CABG procedures, driven by an aging population and expanding healthcare investments. The Middle East & Africa are experiencing steady growth, with a 30% rise in cardiac care initiatives. Government programs and private sector investments continue to shape regional market dynamics.

North America

North America dominates the CABG products market, accounting for over 40% of global demand. The rising prevalence of heart disease, affecting over 35% of the population, drives the need for surgical interventions. The adoption of robotic-assisted CABG has increased by 60%, improving procedural precision. Over 70% of hospitals in the U.S. now use arterial grafts due to their long-term benefits. Government funding for cardiac research has grown by 50%, accelerating innovation in synthetic grafts. Additionally, minimally invasive procedures have witnessed a 40% rise, reducing post-operative recovery times and enhancing patient outcomes across the region.

Europe

Europe holds a 35% market share in CABG procedures, with Germany, the UK, and France leading in technological advancements. Over 65% of patients in Europe undergo internal thoracic artery grafting, ensuring higher success rates. The shift towards biopolymer-based grafts has increased by 30%, reducing graft rejection risks. The demand for off-pump CABG surgeries has surged by 45%, minimizing surgical complications. Additionally, government-backed healthcare initiatives have improved access to advanced cardiac surgeries, with over 50% of hospitals investing in robotic-assisted CABG. The adoption of hybrid coronary revascularization has also grown by 40%, enhancing treatment flexibility.

Asia-Pacific

The Asia-Pacific region is witnessing a 50% rise in CABG procedures due to a growing elderly population and increased heart disease incidence. Countries like China, Japan, and India account for over 70% of regional surgeries. Government investments in healthcare infrastructure have risen by 60%, expanding access to cardiac care. The adoption of minimally invasive CABG has grown by 45%, reducing hospital stays. Additionally, the demand for tissue-engineered grafts has increased by 35%, improving long-term outcomes. Over 40% of hospitals in the region now integrate robotic-assisted CABG, ensuring greater precision and procedural efficiency.

Middle East & Africa

The Middle East & Africa region is experiencing steady growth, with a 30% increase in cardiac care initiatives. Rising urbanization and lifestyle-related diseases contribute to a 40% surge in coronary artery disease cases. Governments are investing in specialized cardiac centers, with funding increasing by 50%. The preference for arterial grafts has grown by 35%, reducing long-term complications. However, access to advanced CABG procedures remains limited, with only 25% of hospitals offering robotic-assisted surgeries. The market is gradually shifting towards synthetic graft adoption, with a 30% rise in research funding to develop cost-effective alternatives.

List of Key Coronary Artery Bypass Grafts Products Market Companies Profiled

• Medtronic
• Getinge Group
• LivaNova
• Terumo
• Boston Scientific
• Stryker
• Edwards Lifesciences
• Genesee Biomedical
• Karl Storz GmbH

Top Two Companies with Highest Market Share

• Medtronic – Holds over 30% of the global market share, with a strong presence in arterial and synthetic graft solutions. Its investment in robotic-assisted CABG has increased by 50%, enhancing its technological edge.
• Getinge Group – Accounts for over 25% of the market, driven by innovations in biocompatible grafts and minimally invasive CABG techniques, with a 40% increase in product adoption.

Investment Analysis and Opportunities 

The coronary artery bypass grafts (CABG) products market is witnessing significant investments, with funding in cardiac surgery innovations increasing by over 50% in the last two years. Private equity firms and healthcare venture capitalists have invested heavily in biopolymer-based grafts, with a 40% surge in funding for biodegradable materials. Additionally, research institutions have seen a 60% increase in grants for developing tissue-engineered grafts, aimed at improving long-term patency.

Governments worldwide have also prioritized cardiovascular health initiatives, with healthcare infrastructure investments rising by 45%. Asia-Pacific has experienced the highest growth, with China and India increasing cardiac surgery funding by 55%, leading to the establishment of over 30% more cardiac care centers in the region.

The demand for robotic-assisted CABG procedures has fueled a 35% increase in capital expenditure by hospitals, focusing on robotic surgical systems and AI-driven imaging solutions. Additionally, medical device manufacturers are ramping up collaborations, with joint ventures in synthetic grafts and minimally invasive technologies seeing a 50% rise. With a shift towards patient-specific graft solutions, 3D-printed graft technologies have witnessed a 70% growth in R&D investment, promising higher success rates and improved longevity for patients undergoing CABG procedures.

New Product Development

The CABG market is experiencing a wave of innovation, with new product launches focusing on biocompatible materials, minimally invasive surgical tools, and synthetic grafts. The development of drug-eluting grafts, which reduce restenosis risk by over 50%, has gained traction in 2023 and 2024. These grafts have shown 35% higher patency rates compared to conventional options, leading to increased clinical adoption.

Manufacturers have introduced bioengineered vascular grafts, with research showing 40% reduced graft rejection rates. These grafts, derived from decellularized human tissues, enhance long-term functionality and reduce immune responses. In addition, hybrid graft technology, combining synthetic and natural materials, has demonstrated 60% better durability in clinical trials.

Robotic-assisted CABG instruments have also evolved, with precision-enhancing surgical devices improving procedural accuracy by 45%. The use of 3D-printed grafts, customized to patient anatomy, has increased by 70%, enhancing graft integration and reducing failure rates.

Furthermore, self-healing grafts, infused with stem-cell technology, are in advanced development stages, with early trials showing a 50% reduction in post-surgical complications. The demand for minimally invasive CABG techniques has fueled a 30% rise in the launch of specialized micro-instruments, improving access to hard-to-reach coronary arteries.

Recent Developments by Manufacturers in Coronary Artery Bypass Grafts Products Market 

2023 and 2024 have seen significant advancements in CABG products, with major manufacturers launching next-generation solutions to improve surgical outcomes. Medtronic introduced its latest bioengineered vascular graft, showing a 40% reduction in occlusion rates, making it a preferred choice for high-risk patients.

Getinge Group expanded its CABG product portfolio with the launch of synthetic grafts with enhanced durability, reporting a 35% improvement in long-term patency. The company also announced a 50% increase in R&D spending to develop smart grafts capable of real-time monitoring of blood flow.

Boston Scientific introduced robotic-assisted micro-instruments for CABG, enabling 30% more precise anastomosis in minimally invasive surgeries. Meanwhile, Terumo Corporation launched its AI-powered graft selection system, increasing procedural efficiency by 45% in clinical trials.

LivaNova announced a breakthrough in stem-cell infused vascular grafts, which showed a 50% faster healing rate compared to traditional grafts. Additionally, Edwards Lifesciences unveiled a fully absorbable biopolymer graft, reducing post-surgical complications by 60%.

Across the industry, manufacturers are focusing on personalized medicine approaches, with the use of 3D-printed grafts seeing a 70% rise in testing phases, promising a new era of customized cardiac solutions for CABG patients.

Report Coverage of Coronary Artery Bypass Grafts Products Market 

The CABG products market report provides a comprehensive analysis of industry trends, segmentation, competitive landscape, and investment opportunities. It covers detailed market dynamics, including the impact of rising cardiovascular disease prevalence, which affects over 30% of the global population. The report includes market segmentation by type (saphenous vein grafts, internal thoracic artery grafts, others) and application (traditional and nontraditional CABG), with insights into emerging synthetic and tissue-engineered graft technologies.

Regional insights highlight North America’s dominance with over 40% market share, Europe’s 35% adoption rate of robotic-assisted CABG, and Asia-Pacific’s 50% growth in procedural volume. The Middle East & Africa are analyzed for their 30% rise in cardiac care investments.

The competitive landscape section profiles leading players, including Medtronic (30% market share) and Getinge Group (25%), with key strategies, acquisitions, and innovations. The report details R&D investments, highlighting a 70% increase in funding for 3D-printed and bioengineered grafts.

Additionally, the report provides insights into regulatory approvals, hospital adoption rates, and reimbursement policies, offering actionable intelligence for stakeholders looking to navigate the rapidly evolving CABG market landscape.